Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Relapsed/Refractory Extranodal NK/T Cell Lymphoma
NCT03228836Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2017
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Innovent Biologics. Primary endpoint: Objective Response Rate. Started Aug 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT03228836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228836.